• Patient will complete 4 vaccinations of monthly interval
  

• Evaluation of immune response. Immune response analysis will be done on all patients who are enrolled in the study. Patients who completed a minimum of 4 vaccinations will be included in immune response.
  

To evaluate feasibility and safety of vaccination with allogeneic idiotype-pulsed dendritic cells following mixed chimeric allogeneic transplantation for multiple myeloma.

Inclusion Criteria:1. For specimen collection and idiotype protein development:

• Must be secretory myeloma with at least .5g/dl serum IgG protein
• Clincally stage 2 or 3 multiple myeloma

• Karnofsky performance status of 70 or greater

  2. For Vaccination:

• Eligible patients must have completed tandem autologous and nonmyeloablative allogeneic transplant for multiple myeloma at Stanford University Medical Center with stable disease or complete response to prevaccine therapy
• Karnofsky performance status of 70 or greater.
• ALT and AST must be <2X upper limit of normal. Total blilirubin < 1.5X upper limit of normal.
• Serum creatinine <1.5X upper limit of normal.
• Hemoglobin >9g/dl
• Patients must be HIV negative.

• Patients must provide signed, informed consent

  . Donor Inclusion Criteria (allodonor is the same donor used for non-myeloablative transplant)

• Age >17 years
• HIV negative

• Must provide signed, informed consent Exclusion Criteria:Patient Exclusion Criteria

  1. For specimen collection and idiotype protein development:

• Patients with non-secretory myeloma
• Severe psychological or medical illness
• Pregnant or lactating women
• Subjects with > Grade I toxicity by NCI-CTC v 3.0

• Subjects with prognosis < 6 months

  2. For Vaccination:

• < 75 mg of idiotype protein purified from the patients serum
• < 25 million allogeneic idiotype-pulsed dendritic cells produced for vaccination
• Evidence of grade II-IV acute GVHD (defined in section 5E)
• Patients with evidence of myeloma disease progression as (defined below)
• Severe psychological or medical illness or concomitant medications which may interfere with the study as determined by the clinical investigator
• Patients on any other investigational agents
• Pregnant or lactating women
• Patients on any therapy for multiple myeloma or any chemotherapy drug, or immunomodulatory agent for treatment of multiple myeloma (e.g. thalidomide)

• Any patient on more than two of the following immunosuppressive agents or at a dose greater than that indicated for a single immunosuppressive agent:

  i. Mycophenylate Mofetil (MMF)- no greater than 1000mg twice a day ii. Prednisone- no greater than .5mg/kg/day iii. Cyclosporine- no greater than 300mg/day iv. Tacrolimis (FK506)- no greater than 4mg/day